HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on ZyVersa Therapeutics (NASDAQ:ZVSA) and maintains a $12 price target.

March 26, 2024 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ZyVersa Therapeutics receives a reiterated Buy rating and a maintained $12 price target from HC Wainwright & Co.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. A reiterated Buy rating and a maintained price target suggest a strong conviction in the company's potential, likely leading to positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100